CLINICAL EVALUATION OF ISONIAZID
Authors: S S CUTLER, B BURBANK, B BATTAGLIA
Journal: Annals of Internal Medicine (1953)

Article1 September 1953CLINICAL EVALUATION OF ISONIAZIDSEYMOUR S. CUTLER, M.D., BENJAMIN BURBANK, M.D., F.A.C.P., BIAGIO BATTAGLIA, M.D., F.A.C.P.SEYMOUR S. CUTLER, M.D.Search for more papers by this author, BENJAMIN BURBANK, M.D., F.A.C.P.Search for more papers by this author, BIAGIO BATTAGLIA, M.D., F.A.C.P.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-39-3-444 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptSince 1944, the mainstay in drug therapy of tuberculosis has been streptomycin. This drug, especially in combination with para-amino-salicylic acid (PAS) and when used in dosage schedules designed to delay the emergence of resistant strains of Mycobacterium tuberculosis, has revolutionized the course and the prognosis of pulmonary and extrapulmonary tuberculosis. Nevertheless, the obvious drawbacks of streptomycin, such as its production of neurotoxic symptoms, allergic reactions and bacterial resistance, have encouraged the search for other mycobactericidal agents. A recent advance has been the development of hydrazine derivatives of isonicotinic acid.The most promising of these compounds is isonicotinic acid hydrazide, Isoniazid...Bibliography1. RobitzekSelikoff EHIJ: Hydrazine derivatives of isonicotinic acid (Rimifon, Marsilid) in the treatment of active progressive caseous-pneumonic tuberculosis. A preliminary report, Am. Rev. Tuberc. 65: 402-428 (Apr.) 1952. MedlineGoogle Scholar2. SelikoffRobitzekOrnstein IJEHGG: Treatment of pulmonary tuberculosis with hydrazide derivatives of isonicotinic acid, J. A. M. A. 150: 973-980 (Nov. 8) 1952. CrossrefMedlineGoogle Scholar3. ClarkElmendorfCawthonMuschenheimMcDermott GMDMWUCW: Isoniazid (isonicotinic acid hydrazide) in the treatment of miliary and meningeal tuberculosis, Am. Rev. Tuberc. 66: 391-415 (Oct.) 1952. MedlineGoogle Scholar4. NashGrosfeld JCW: Isoniazid and iproniazid resistance in pulmonary tuberculosis, J. A. M. A. 150: 813 (Oct. 25) 1952. CrossrefGoogle Scholar5. Suter E: Action of streptomycin and isonicotinic acid hydrazide on Mycobacterium tuberculosis within phagocytes, Am. Rev. Tuberc. 63: 775 (June) 1952. Google Scholar6. British experience with Isoniazid. Foreign letters (London), J. A. M. A. 150: 1138 (Nov. 15) 1952. Google Scholar7. ElmendorfCawthonMuschenheimMcDermott DMWUCW: The absorption, distribution, excretion, and short-term toxicity of isonicotinic acid hydrazide (Nydrazid) in man, Am. Rev. Tuberc. 65: 420-442 (Apr.) 1952. Google Scholar8. CanettiSaeng GA: La streptomycino-résistance de souches de bacilles de Koch provenant de lésions pulmonaires différentes d'un meme malade, Ann. Inst. Pasteur 80: 238 (Mar.) 1951; abstracted, Am. Rev. Tuberc. 64: 95 (Nov.) 1951. MedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Brooklyn, N. Y.*Received for publication March 27, 1953.From the Department of Medicine, College of Medicine, State University of New York. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 September 1953Volume 39, Issue 3Page: 444-462KeywordsAllergy and immunologyDrug therapyDrugsIsoniazidMycobacterium tuberculosisPeriodic acid SchiffStreptomycin ePublished: 1 December 2008 Issue Published: 1 September 1953 PDF downloadLoading ...